An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy
Interventional
Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Number of participants with adverse events.
Lance Leopold, MD
Study Director
Ascenta Therapeutics, Inc.
United States: Food and Drug Administration
AT-101-CS-006
NCT00286806
December 2005
June 2007
Name | Location |
---|---|
New Britain, Connecticut 06052 | |
Fountain Valley, California 92708 | |
Nashville, Tennessee 37203-1632 | |
Milwaukee, Wisconsin |